

4A

16238

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 2nd day of December 2003



By

(Signature of person mailing)
Patricia Botelho

(Typed or printed name of person)

PC10920ARTR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Simon John Mantell et al.

: EXAMINER: Josephine Young

SERIAL NO.: 09/884,244

: ART UNIT: 1623

FILED: June 19, 2001

:

FOR: Histamine Receptor Antagonists

:

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RECEIVED
DEC 09 2003
TECH CENTER 1600/2900

Sir:

Terminal Disclaimer

The owner, Pfizer Inc., of 100 percent interest in the instant patent application, hereby makes the following disclaimer.

The above-identified application has been rejected for obviousness-type double patenting over commonly owned US patent 6,326,359, filed October 15, 1999 as a continuation of a copending International application filed on October 5, 1999. Any patent issuing on the instant application would ordinarily expire on June 19, 2021. Applicants hereby disclaim the term of any patent issuing from the instant application which extends beyond the term of US patent 6,326,359.

The owner hereby agrees that any patent granted on the instant application shall be enforceable only for and during the period that it and US 6,326,359 are and remain commonly owned. Any patent granted on the instant application shall cease to be enforceable at the time that common ownership ceases, although US 6,326,359 shall remain in force and be enforceable for any remainder of its statutory term as defined in 35 USC 154 to 156 and 173. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

The undersigned is an attorney of record.

12/05/2003 SSITHIB1 00000056 161445 09884244

01 FC:1814 110.00 DA

Please charge the \$110.00 fee under 37 CFR 1.20(d) to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Date: December 2, 2003

Respectfully submitted,

Robert T. Ronau
Robert T. Ronau
Attorney for Applicant(s)
Reg. No. 36,257

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-5910